The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: Responders, hyper-responders, and non-responders

Transfusion Medicine and Hemotherapy

Volumn 41, Issue 6, 2014, Pages 420-429

  Gehrie, Eric A ^a   Tormey, Christopher A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Alloimmunization; Blood group antigens; Immunohematology; Responders

Indexed keywords

ALLOANTIBODY; BIOLOGICAL MARKER; ERYTHROCYTE ANTIBODY; ERYTHROCYTE ANTIGEN; HEMOGLOBIN; RHESUS ANTIGEN;

ALLOIMMUNIZATION; ANTIBODY RESPONSE; BLOOD PROTEIN DISORDER; CANCER PATIENT; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; GENETIC ASSOCIATION; GROUPS BY AGE; HEMATOLOGIC DISEASE; HOSPITAL PATIENT; HUMAN; INFLAMMATION; LEUKOCYTE; MEDICAL LITERATURE; NEWBORN; NONHUMAN; NORMAL HUMAN; ORGAN TRANSPLANTATION; POPULATION RESEARCH; REVIEW; SEX;

EID: 84918508153     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000369109     Document Type: Review

References (87)

1. Fong SW, Qaqundah BY, Taylor WF: Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion 1974;14:551-559.
2. Davenport RD: Pathophysiology of hemolytic transfusion reactions. Semin Hematol 2005;42:165-168.
3. United States Food and Drug Administration: CBER, 2012. www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/ (last accessed October 16, 2014).
4. Serious Hazards of Transfusion: Annual report, 2012. www.shotuk.org (last accessed October 16, 2014).
5. Booth GS, Gehrie EA, Savani BN: Minor RBC Ab and allo-SCT. Bone Marrow Transplant 2014;49:456-457.
6. Winters JL, Pineda AA, Gorden LD, Bryant SC, Melton LJ 3rd, Vamvakas EC, Moore SB: RBC alloantibody specificity and antigen potency in Olmsted county, Minnesota. Transfusion 2001;41:1413-1420.
7. Spielmann W, Seidl S: Prevalence of irregular red cell antibodies and their significance in blood transfusion and antenatal care. Vox Sang 1974;26:551-559.
8. Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA: Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159, 262 patients from 1985 to 1993. Arch Pathol Lab Med 1995;119:42-45.
9. Thakral B, Saluja K, Sharma RR, Marwaha N: Red cell alloimmunization in a transfused patient population: a study from a tertiary care hospital in North India. Hematology 2008;13:313-318.
10. Higgins JM, Sloan SR: Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008;112:2546-2553.
11. Tormey CA, Fisk J, Stack G: Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008;48:2069-2076.
12. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briet E: Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007;47:2066-2071.
13. Tormey CA, Stack G: Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009;114:4279-4282.
14. Yazer MH, Triulzi DJ: Detection of anti-D in D-recipients transfused with D+ red blood cells. Transfusion 2007;47:2197-2201.
15. Frohn C, Dumbgen L, Brand JM, Gorg S, Luhm J, Kirchner H: Probability of anti-D development in D-patients receiving D+ RBCs. Transfusion 2003;43:893-898.
16. Redman M, Regan F, Contreras M: A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996;71:216-220.
17. Alves VM, Martins PR, Soares S, Araujo G, Schmidt LC, Costa SS, Langhi DM, Moraes-Souza H: Alloimmunization screening after transfusion of red blood cells in a prospective study. Rev Bras Hematol Hemoter 2012;34:206-211.
18. Schabel A, Konig AL, Schiebel MR, Sugg U: Incidence and persistence of anti-Kell after transfusion of Kell-positive blood. Beitr Infusionsther Transfusionsmed 1994;32:175-178.
19. Tormey CA, Stack G: The characterization and classification of concurrent blood group antibodies. Transfusion 2009;49:2709-2718.
20. Schonewille H, Brand A: Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens? Transfusion 2008;48:958-963.
21. Gunson HH, Stratton F, Cooper DG, Rawlinson VI: Primary immunization of Rh-negative volunteers. BMJ 1970; i: 593-595.
22. Urbaniak SJ, Robertson AE: A successful program of immunizing Rh-negative male volunteers for anti-D production using frozen/thawed blood. Transfusion 1981;21:64-69.
23. Floss AM, Strauss RG, Goeken N, Knox L: Multiple transfusion fail to provoke antibodies against blood cell antigens in human infants. Transfusion 1986;26:419-422.
24. Ludvigsen CW Jr, Swanson JL, Thompson TR, McCullough J: The failure of neonates to form red blood cell alloantibodies in response to multiple transfusions. Am J Clin Pathol 1987;87:250-251.
25. DePalma L, Criss VR, Roseff SD, Luban NL: Presence of the red cell alloantibody anti-E in an 11-week-old infant. Transfusion 1992;32:177-179.
26. Marsh WL, Nichols ME, Oyen R, Thayer RS, Deere WL, Freed PJ, Schmelter SE: Naturally occurring anti-Kell stimulated by E.coli enterocolitis in a 20-day-old child. Transfusion 1978;18:149-154.
27. Hata JL, Johnson MS, Booth GS: Neonatal alloimmunization: a rare case of multiple alloantibody formation in a patient with disseminated histoplasmosis. Transfusion 2013;53:1140-1141.
28. Tyler LN, Harville TO, Blackall DP: Multiple alloantibodies after transfusion in an infant treated with infliximab. N Engl J Med 2007;357:2092-2093; discussion 2093.
29. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B: Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617-1621.
30. Sarnaik S, Schornack J, Lusher JM: The incidence of development of irregular red cell antibodies in patients with sickle cell anemia. Transfusion 1986;26:249-252.
31. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, Levy PS: Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431-1437.
32. Orlina AR, Unger PJ, Koshy M: Post-transfusion alloimmunization in patients with sickle cell disease. Am J Hematol 1978;5:101-106.
33. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V: Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.
34. Coles SM, Klein HG, Holland PV: Alloimmunization in two multitransfused patient populations. Transfusion 1981;21:462-466.
35. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C: Red cell alloantibodies in patients with thalassemia. Vox Sang 1990;58:50-55.
36. Ameen R, Al-Shemmari S, Al-Humood S, Chowdhury RI, Al-Eyaadi O, Al-Bashir A: RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients. Transfusion 2003;43:1604-1610.
37. Wang LY, Liang DC, Liu HC, Chang FC, Wang CL, Chan YS, Lin M: Alloimmunization among patients with transfusion-dependent thalassemia in Taiwan. Transfus Med 2006;16:200-203.
38. Gonzalez-Porras JR, Graciani IF, Perez-Simon JA, Martin-Sanchez J, Encinas C, Conde MP, Nieto MJ, Corral M: Prospective evaluation of a transfusion policy of D+ red blood cells into D-patients. Transfusion 2008;48:1318-1324.
39. Schonewille H, Haak HL, van Zijl AM: Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999;39:763-771.
40. Arriaga F, Bonanad S, Larrea L, de la Rubia J, Lopez F, Sanz MA, Sanz G, Marty ML: Immunohematologic study in 112 patients with myelodysplastic syndromes: 10-year analysis (in Spanish). Sangre 1995;40:177-180.
41. Novaretti MC, Sopelete CR, Velloso ER, Rosa MF, Dorlhiac-Llacer PE, Chamone DA: Immunohematological findings in myelodysplastic syndrome. Acta Haematol 2001;105:1-6.
42. Stiegler G, Sperr W, Lorber C, Fabrizii V, Hocker P, Panzer S: Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol 2001;80:330-333.
43. Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A: Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion 2013;53:710-715.
44. Young PP, Goodnough LT, Westervelt P, Diersio JF: Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:1305-1310.
45. de La Rubia J, Arriaga F, Andreu R, Sanz G, Jimenez C, Vicente A, Carpio N, Marty ML, Sanz MA: Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor? Transfusion 2001;41:106-110.
46. Ting A, Pun A, Dodds AJ, Atkinson K, Biggs JC: Red cell alloantibodies produced after bone marrow transplantation. Transfusion 1987;27:145-147.
47. Cid J, Ortin X, Elies E, Castella D, Panades M, Martin-Vega C: Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion 2002;42:173-176.
48. Ramsey G, Hahn LF, Cornell FW, Boczkowski DJ, Staschak S, Clark R, Hardesty RL, Griffith BP, Starzl TE: Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery. Transplantation 1989;47:993-995.
49. Casanueva M, Valdes MD, Ribera MC: Lack of alloimmunization to D antigen in D-negative immunosuppressed liver transplant recipients. Transfusion 1994;34:570-572.
50. Yuan S, Davis R, Lu Q, Goldfinger D, Ziman AF: Low risk of alloimmunization to the D antigen in D-orthotopic liver transplant recipients receiving D+ RBCs perioperatively. Transfusion 2008;48:2653-2655.
51. Schonewille H, van de Watering LM, Brand A: Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006;46:630-635.
52. Tormey CA, Stack G: Pre-existing non-ABO blood group alloantibodies identify a 'responder' subgroup prone to subsequent red cell alloimmunization. Transfusion 2013;53(suppl 2):150a.
53. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F: Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012;120:528-537.
54. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM: High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122:1062-1071.
55. Brantley SG, Ramsey G: Red cell alloimmunization in multitransfused HLA-typed patients. Transfusion 1988;28:463-466.
56. ∗0901. Transfusion 2009;49:472-478.
57. Reviron D, Dettori I, Ferrera V, Legrand D, Touinssi M, Mercier P, de Micco P, Chiaroni J: HLA-DRB1 alleles and Jka immunization. Transfusion 2005;45:956-959.
58. ∗07:01 allele is primarily associated with the Diego a alloimmunization in a Brazilian population. Transfusion 2014;54:2468-2476.
59. Schonewille H, Doxiadis II, Levering WH, Roelen DL, Claas FH, Brand A: HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion 2014;54:1971-1980.
60. Noizat-Pirenne F, Tournamille C, Bierling P, Roudot-Thoraval F, Le Pennec PY, Rouger P, Ansart-Pirenne H: Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. Transfusion 2006;46:1328-1333.
61. Tatari-Calderone Z, Tamouza R, Le Bouder GP, Dewan R, Luban NL, Lasserre J, Maury J, Lionnet F, Krishnamoorthy R, Girot R, Vukmanovic S: The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol 2013;2013:937846.
62. Zimring JC, Hendrickson JE: The role of inflammation in alloimmunization to antigens on transfused red blood cells. Curr Opin Hematol 2008;15:631-635.
63. Hendrickson JE, Desmarets M, Deshpande SS, Chadwick TE, Hillyer CD, Roback JD, Zimring JC: Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 2006;46:1526-1536.
64. Hendrickson JE, Chadwick TE, Roback JD, Hillyer CD, Zimring JC: Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood 2007;110:2736-2743.
65. Hendrickson JE, Roback JD, Hillyer CD, Easley KA, Zimring JC: Discrete Toll-like receptor agonists have differential effects on alloimmunization to transfused red blood cells. Transfusion 2008;48:1869-1877.
66. Ramsey G, Smietana SJ: Multiple or uncommon red cell alloantibodies in women: association with autoimmune disease. Transfusion 1995;35:582-586.
67. Papay P, Hackner K, Vogelsang H, Novacek G, Primas C, Reinisch W, Eser A, Mikulits A, Mayr WR, Kormoczi GF: High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. Am J Med; 125:717 e711-718.
68. Yazer MH, Triulzi DJ, Shaz B, Kraus T, Zimring JC: Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion 2009;49:1070-1075.
69. Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiebaut R, Tibshirani RJ, Davis MM: Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A 2014;111:869-874.
70. Giblett ER: Blood group alloantibodies: an assessment of some laboratory practices. Transfusion 1977;17:299-308.
71. Fluit CR, Kunst VA, Drenthe-Schonk AM: Incidence of red cell antibodies after multiple blood transfusion. Transfusion 1990;30:532-535.
72. Verduin EP, Brand A, Schonewille H: Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. Transfus Med Rev; 26:342-353, 353 e1-5.
73. Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, Marcato A, Passeri G, Ortolani C, Forti E, et al.: Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993;82:2767-2773.
74. Hendrickson JE, Tormey CA, Shaz BH: Red blood cell alloimmunization mitigation strategies. Transfus Med Rev 2014;28:137-144.
75. Castro O, Sandler SG, Houston-Yu P, Rana S: Predicting the effect of transfusing only phenotypematched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002;42:684-690.
76. Ambruso DR, Githens JH, Alcorn R, Dixon DJ, Brown LJ, Vaughn WM, Hays T: Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94-98.
77. Lau FY, Wong R, Chan NP, Chui CH, Ng E, Ng MH, Cheng G: Provision of phenotype-matched blood units: no need for pre-transfusion antibody screening. Haematologica 2001;86:742-748.
78. Osby M, Shulman IA: Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005;129:190-193.
79. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B: Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012;157:49-58.
80. Sanz C, Ghita G, Franquet C, Martinez I, Pereira A: Red-blood-cell alloimmunization and female sex predict the presence of HLA antibodies in patients undergoing liver transplant. Vox Sang 2010;99:261-266.
81. Schonewille H, Brand A: Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study. Br J Haematol 2005;129:151-156.
82. Ramsey G, Larson P: Loss of red cell alloantibodies over time. Transfusion 1988;28:162-165.
83. Ramsey G, Smietana SJ: Long-term follow-up testing of red cell alloantibodies. Transfusion 1994;34:122-124.
84. Tormey CA, Stack G: The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009;49:505-512.
85. Unni N, Peddinghaus M, Tormey CA, Stack G: Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion 2014;54:98-103.
86. Chown B: Prevention of Rh immunization. Can Med Assoc J 1969;100:869.
87. Boctor FN, Ali NM, Mohandas K, Uehlinger J: Absence of D-alloimmunization in AIDS patients receiving D-mismatched RBCs. Transfusion 2003;43:173-176.